Fernández-Martos C, Pericay C, Losa F, et al. - In patients with high-risk rectal adenocarcinoma, researchers analyzed the impact of aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction CT prior to standard CRT and total mesorectal excision surgery. According to results, the proportion achieving a pathologic complete response was 22.6% with aflibercept vs 13.8% without in this phase 2 randomized clinical trial of 180 individuals with rectal adenocarcinoma. In patients with high-risk rectal adenocarcinoma, adding aflibercept to an induction regimen using mFOLFOX6 plays a role in increasing the pCR rate without significantly increasing surgical complications. A rationale for phase 3 trials was gained in the GEMCAD 1402 trial.